Holen Sie sich die Stockscreener-App
79.61
1.35%
1.06
Handel nachbörslich:
79.61
Schlusskurs vom Vortag:
$78.55
Offen:
$78.94
24-Stunden-Volumen:
1.03M
Relative Volume:
1.03
Marktkapitalisierung:
$4.21B
Einnahmen:
$2.04M
Nettoeinkommen (Verlust:
$-162.34M
KGV:
-19.36
EPS:
-4.1129
Netto-Cashflow:
$-129.27M
1W Leistung:
+0.95%
1M Leistung:
+53.48%
6M Leistung:
+122.13%
1J Leistung:
+335.27%
1-Tages-Spanne:
$78.94
$82.14
1-Wochen-Bereich:
$75.50
$82.49
52-Wochen-Spanne:
$13.37
$88.02
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Firmenname
Dianthus Therapeutics Inc
Sektor
Branche
Telefon
929-999-4055
Adresse
7 TIMES SQUARE, NEW YORK
Compare DNTH vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
79.61 | 4.16B | 2.04M | -162.34M | -129.27M | -4.1129 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-10-14 | Eingeleitet | Truist | Buy |
| 2025-07-02 | Eingeleitet | William Blair | Outperform |
| 2024-12-20 | Eingeleitet | TD Cowen | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-15 | Eingeleitet | Stifel | Buy |
| 2023-12-26 | Eingeleitet | Jefferies | Buy |
| 2023-11-22 | Eingeleitet | Wedbush | Outperform |
| 2023-10-30 | Eingeleitet | Guggenheim | Buy |
| 2023-09-28 | Eingeleitet | Raymond James | Outperform |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-06 | Hochstufung | Goldman | Neutral → Buy |
| 2021-08-20 | Fortgesetzt | Goldman | Neutral |
| 2021-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Bestätigt | B. Riley Securities | Buy |
| 2021-06-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-18 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-07 | Eingeleitet | Mizuho | Buy |
| 2020-06-08 | Hochstufung | Goldman | Neutral → Buy |
| 2019-03-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Dianthus Therapeutics Inc Aktie (DNTH) Neueste Nachrichten
[144] Dianthus Therapeutics, Inc.... | DNTH SEC FilingForm 144 - Stock Titan
Wedbush keeps outperform on Dianthus Therapeutics, Inc. (DNTH), highlights potential of Claseprubart in CIDP - MSN
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit - AOL.com
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Dianthus Therapeutics, Inc. (DNTH) reports Q4 loss, misses revenue estimates - MSN
Dianthus Therapeutics, Inc. (DNTH) stock jumps 12.0%: Will it continue to soar? - MSN
Assessing Dianthus Therapeutics (DNTH) Valuation After CAPTIVATE Milestone And Upsized Equity Offering - simplywall.st
Dianthus Therapeutics has appreciated 12-fold over two years. What's going on? - MSN
Wells Fargo Initiates Coverage on Dianthus Therapeutics - National Today
Wells Fargo & Company Initiates Coverage on Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat
Wells Fargo Initiates Dianthus Therapeutics at Overweight - marketscreener.com
Wells Fargo reiterates Dianthus Therapeutics stock rating at Overweight By Investing.com - Investing.com Canada
Dianthus Therapeutics shares jump 25% after encouraging clinical trial update - MSN
This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Sahm
Guggenheim reiterates buy rating for Dianthus Therapeutics (DNTH) - MSN
Wedbush Keeps Outperform on Dianthus Therapeutics, Inc. (DNTH), Highlights Potential of Claseprubart in CIDP - Insider Monkey
Biotech shares soar by 288% following a major funding round, with an early investor disclosing a $14 million cash-out - Bitget
Top 5 Boring Stocks That Make Money - Insider Monkey
[Form 4] Dianthus Therapeutics, Inc. /DE/ Insider Trading Activity - Stock Titan
William Blair Maintains Outperform on Dianthus Therapeutics (DNTH) March 2026 - Meyka
Dianthus Therapeutics closes $719M public offering - Investing.com Nigeria
HighVista Strategies Boosts Stake in Dianthus Therapeutics - National Today
HighVista Strategies LLC Buys 38,364 Shares of Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics Raises $719M in Upsized Offering - National Today
Dianthus Therapeutics, Inc. $DNTH is Fairmount Funds Management LLC's Largest Position - MarketBeat
Boothbay Fund Management Buys Stake in Dianthus Therapeutics - National Today
Boothbay Fund Management LLC Buys Shares of 138,963 Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics (DNTH) Is Up 19.4% After Early CAPTIVATE GO Decision And $719M Raise - simplywall.st
Dianthus Therapeutics Hits Early “Go” in CAPTIVATE Phase 3 CIDP Trial, Drops 600 mg Arm - MarketBeat
Braidwell LP Purchases Shares of 835,057 Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics announces proposed $400 million public share offering - MSN
Dianthus Therapeutics EVP Sells $2.7M in Stock - National Today
Assessing Dianthus Therapeutics (DNTH) Valuation After Early CAPTIVATE GO Decision And Premium P/B Multiple - Sahm
Dianthus Therapeutics launches $400M stock offering - Investing.com Nigeria
Integral Health Asset Management Acquires 150,000 Shares in Dianthus Therapeutics - National Today
Integral Health Asset Management LLC Buys New Stake in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics EVP Sells $2.76M in Stock - National Today
Dianthus therapeutics CAO sells shares for $3.56 million - Investing.com Nigeria
Dianthus therapeutics CAO sells shares for $3.56 million By Investing.com - Investing.com Australia
Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) CAO Sells 43,682 Shares of Stock - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) CEO Sells 122,918 Shares - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $2,756,468.40 in Stock - MarketBeat
Dianthus therapeutics CEO Garcia sells $10m in shares - Investing.com
Dianthus Therapeutics EVP Randhawa sells shares for $2.76 million By Investing.com - Investing.com Nigeria
Dianthus Therapeutics EVP Randhawa sells shares for $2.76 million - Investing.com
Dianthus Therapeutics Executives Sell Off Significant Shares - TradingView
Dianthus Therapeutics closes $719M public offering By Investing.com - Investing.com Australia
Dianthus Therapeutics Announces Major Public Equity Offering - The Globe and Mail
Dianthus Therapeutics stock surges 25% on positive trial data - Investing.com Nigeria
Finanzdaten der Dianthus Therapeutics Inc-Aktie (DNTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):